Serum concentrations and side effects in psychiatric patients during risperidone therapy.
作者： Ole V. Olesen , Rasmus W. Licht , Erik Thomsen , Troels Bruun , Jens Emil Viftrup
DOI: 10.1097/00007691-199808000-00004
关键词: Therapeutic drug monitoring 、 Internal medicine 、 Risperidone 、 Oral administration 、 Drug interaction 、 Endocrinology 、 Toxicity 、 Moiety 、 Pharmacology 、 Metabolite 、 Pharmacokinetics 、 Medicine
摘要: SummarySteady state serum concentrations of risperidone and 9-hydroxyrisperidone(9-OH-risperidone), the active moiety, were measured in 42 patients. The concentration-to-dose ratios (C/D) varied by a factor 20, from 1.8 to 36.8(nmol/1)/(mg/24 hours), 90% moiety was constituted o
core.ac.uk
sci-hub.st 参考文章(14)
Risperidone in the treatment of schizophrenia. American Journal of Psychiatry. ,vol. 151, pp. 825- 835 ,(1994) , 10.1176/AJP.151.6.825
May-Lynn Huang, Achiel Van Peer, Robert Woestenborghs, Roland De Coster, Jos Heykants, Arno A I Jansen, Zbigniew Zylicz, Hendrik W Visscher, Jan H G Jonkman, Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clinical Pharmacology & Therapeutics. ,vol. 54, pp. 257- 268 ,(1993) , 10.1038/CLPT.1993.146
Terence A. Ketter, David A. Flockhart, Robert M. Post, Kirk Denicoff, Peggy J. Pazzaglia, Lauren B. Marangell, Mark S. George, Ann M. Callahan, The Emerging Role of Cytochrome P450 3A in Psychopharmacology Journal of Clinical Psychopharmacology. ,vol. 15, pp. 387- 398 ,(1995) , 10.1097/00004714-199512000-00002
A. Schotte, P.F.M. Janssen, A.A.H.P. Megens, J.E. Leysen, Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography. Brain Research. ,vol. 631, pp. 191- 202 ,(1993) , 10.1016/0006-8993(93)91535-Z
E. Snoeck, A. Van Peer, G. Mannens, R. Woestenborghs, J. Heykants, M. Sack, M. Horton, R. Meibach, Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man Psychopharmacology. ,vol. 122, pp. 223- 229 ,(1995) , 10.1007/BF02246543
H. He, J. S. Richardson, A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors International Clinical Psychopharmacology. ,vol. 10, pp. 19- 30 ,(1995) , 10.1097/00004850-199503000-00003
T. sumiyoshi, H. Kido, H. Sakamoto, K. Urasaki, K. Suzuki, N. Yamaguchi, H. Mori, K. Shiba, K. Yokogawa, In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacology, Biochemistry and Behavior. ,vol. 47, pp. 553- 557 ,(1994) , 10.1016/0091-3057(94)90158-9
GUY CHOUINARD, BARRY JONES, GARY REMINGTON, DAVID BLOOM, DONALD ADDINGTON, G. WILLIAM MacEWAN, ALAIN LABELLE, LINDA BEAUCLAIR, WENDY ARNOTT, A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients Journal of Clinical Psychopharmacology. ,vol. 13, pp. 25???40- 40 ,(1993) , 10.1097/00004714-199302000-00004
K. G. Jostell, D. Fagan, M. Björk, F. Broberg, R. M. Mitchell, D. B. Scott, B. Ulff, The bioavailability and pharmacodynamics of chlormethiazole in healthy young and elderly volunteers: preliminary findings. Acta Psychiatrica Scandinavica. ,vol. 73, pp. 32- 33 ,(1986) , 10.1111/J.1600-0447.1986.TB10532.X
Ludy E. C. van Beijsterveldt, Rita J. F. Geerts, Josée E. Leysen, Anton A. H. P. Megens, Hilde M. J. Van den Eynde, Willem E. G. Meuldermans, Jozef J. P. Heykants, Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat Psychopharmacology. ,vol. 114, pp. 53- 62 ,(1994) , 10.1007/BF02245444